
Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD
<a href="https://news.google.com/rss/articles/CBMiigNBVV95cUxQOFpqdXVnTXJuVTNYdnJtSl9Bb09xeEsyeUJ5RFNTUC0wbF9ETjJqUVF5TmVhemxJbkNIbVhHOU41dVE1LVRoeF80Vld5eVdMbUdOanl0MnJCbnlQS2lzR3IxeXhCUjdiOFdXd1h3a284MHpnTEI5VU9uMlhvTElDaDBXOGxLZWhseDdEanZOY3JXbXlrTXVsNmxmdXRzMFZaeG51UjhXUW9ZR1QtVjRQNGtQemlpQmNwSHJkM2FXZ1p3YXVCVDBCbVBvZGRDM05NQVZiMm9fTm04UVpFRnRBVkVuYmc4WXluMmxEV1Nyd296eldldHdTU1d5VWFyRlFEOVZYNXVMTU5jWFF0MUF0UUg5OVpheGswamR5SGJfakpNU2VNZWdjYk90LWpqUVQ1eERHZmhUX1VCazh2c1pZVWY2czR0LWpWSERRY2J6d1EzYmJyNEktNXhhY0xyeWxQMnVNS2d3S3YzU2p0by1FdjhLdU9ESzU1YWxKcUdZdy1VamViRnRfVDlB?oc=5" target="_blank">Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
